CRD Summary: The authors concluded that limited evidence showed no benefit of mycophenolate mofetil in moderately advanced IgA nephropathy and a reduction in proteinuria in less advanced disease. There were limitations in reporting of review methods and conclusions were based on limited evidence, so any conclusions should be interpreted with caution.

CRD Commentary:  The review question was clearly stated. Inclusion criteria were clearly stated, but not adhered to. Eligible studies were those that compared mycophenolate mofetil with other immunosuppressive agents, but only one study that used prednisolone as the control met these criteria. Other studies used ACEI/ARB or placebo as controls and these agents are not immunosuppressive. Several relevant sources were searched and no language restrictions were applied, but no attempts were made to minimise publication bias. Methods were used to minimise reviewer errors and bias in the extraction of data, but it was unclear whether similar steps were taken in study selection and validity assessment. Validity was assessed and results were reported. Pooling only comparable studies was appropriate. There were limitations in reporting of review methods and conclusions were based on limited evidence, so any conclusions should be interpreted with caution.